Preparation for infusion pander), hydroxyethyl starch.'-3t Furthermore, the experiments were designed to compare the effectiveness of direct perfusion of a "test" vein segment with indirect perfusion of a vein segment by systemic administration. one of the veins, but only systemic perfusion of the other ( fig. 1 ). The method of inducing thrombosis has been previously reported4' 5 and in brief, consisted of the passage of a 10-ma direct current through the vein wall for 1 hour. During the hour of application of current, one of the four test solutions was administered at a rate calculated to comprise a dosage equal in volume to 2% of the body weight in kilograms. The solutions employed were (1) 2.5% dextrose in 0.45% sodium chloride (hereafter referred to as the "control solution"); (2) 10% low molecular-weight dextran (average molecular weight, 40,000) in 0.85% sodium chloride; (3) 6% dextran (average molecular weight, 75,000) in 0.85% sodium chloride; and (4) 6% hydroxyethyl starch ("intrinsic viscosity," 0.16 to 0.19) in 0.85% sodium chloride.
Four groups of 10 dogs each received one of these test solutions. Following the period of electrical current application and administration of solution, the incision was closed and the dogs were placed in cages. Six hours after completion of the fluid administration, additional anesthetic was administered if necessary; the groin incisions were reopened and the veins exposed for evaluation of venous clotting.
Assessment of the occurrence and magnitude of the venous clot was carried out in two major fashions, utilizing several parameters of observation: (1) Clot propagation was estimated by recording the measured length of the clot in situ.
(2) Magnitude of thrombosis was estimated by the following descriptive schema: 0, no clot; +, a nonocclusive clot less than 1 cm long; + +, a nonocclusive clot greater than 1 cm long; and + + +, a completely occlusive clot.
The degree of occlusiveness of the thrombus was determined by observing blood flow from a small incision in the vein, after placing a clamp proximal to the test segment at the level of the femoral ring. The veins were then ligated distally, opened, and the clot further examined by direct measurement in situ.
Results
The data acquired in these studies may be presented in two major catagories: (1) propagation of the clot (expressed as mean clot length in centimeters), and (2) magnitude of venous occlusion produced by the clot (table 1) . Figure 2 depicts the mean clot length observed in the femoral veins of the limbs directly perfused as compared with the mean clot length in the veins perfused only by systemic administration of the various agents. The graph demonstrates that clot propagation was significantly reduced in the limbs which were directly perfused.
Propagation of Clot
In figure 3 , the mean clot length for each of the four listed groups of agents is demonstrated. A statistical evaluation of these data expressed by standard error reveals that in those limbs directly perfused by the agents there were no valid differences in clot propagation manifested by mean clot length among the four test groups of animals. On the other hand, in the four groups of systemic-infused limbs, significant protection against clot propagation is afforded by the plasma expanders as compared to the control, glucose-saline solution. Both low molecular-weight dextran and "clinical dextran" produced a similar consistent decrement (statistically valid) in mean clot length, as compared to the controls. The decrease in mean clot length in the hydroxyethyl starch-treated group was not statistically valid when compared to the controls. This variance in mean clot lengths apparently resulted from unusually long clots (6 cm) in two of the 10 dogs in the starch group. bosis two parameters were observed: (1) length of the clot and (2) degree of occlusion of the lumen of the vein. Clots less than 1 cm in length were arbitrarily termed "insignificant" (no such clots were totally occlusive). Table 2 further confirms the previous impression that direct infusion of the solutions distal to the point of injury in the veins provided significantly greater protection from thrombosis than did systemic administration of the agent. Both the incidence of significant clots and the degree of occlusiveness of such clots were reduced by direct perfusion. Throughout the tables a significant clot is (low viscosity) (P < 0.25) (P < 0.07) *Significant thrombosis = all occlusive and nonocclusive clots greater than 1 cm in length.
tPer cent of group.
administration of either low molecular-weight dextran or clinical dextran.
Discussion
The concept that plasma expanders may inhibit blood coagulation is not recent. Shortly after the introduction of the dextrans into clinical medicine in 1944, a flurry of reports appeared in the literature describing various alterations of blood coagulation following the addition or administration of dextran solutions of a molecular weight range approximating those now used clinically as "clinical dextran" (molecular weight, 75,000). These reports were summarized and reviewed in an extensive investigation of the effect of dextrans upon coagulation by Jacobaeus.6 He described some 20 alterations in the coagulation mechanism presumably resulting from the addition of dextran to blood.
In the early 1960's, a transition in perspective appeared regarding the capability of dextran to inhibit blood coagulation. Bloom, Bryant, and associates7' 8, 9 first generated the hypothesis that the capability of dextran to inhibit clotting could be used with benefit to retard or inhibit intravascular thrombosis. Thus, the antithrombotic property of an agent may be construed as beneficial if the desired therapeutic effect is that of inhibiting clotting, or as deleterious if the clinical problem creates concern for the integrity of the hemostatic mechanism.
Circulation, Volume XXXIII, June 1966 Since 1961, several others have conducted comparative studies of the efficacy of dextran solutions to inhibit or retard intravascular thrombosis. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] Our own investigations in this area followed studies concerning the effect of low molecularweight dextran in inhibiting intravascular sludging (believed by some to be a precursor to intravascular thrombosis). These led to the present investigation. Our results are somewhat in conflict with those of previous investigators. It is possible that the apparent variances in results and conclusions among the prior investigations and this present report may be explained on the basis of difference in methods and differences in interpretation of the results occasioned by different dosage schedules.
Just-Viera and Yeager'0 conducted extensive studies relating to this problem. Their recent report described an investigation similar to the present one, testing and comparing the antithrombogenic properties of clinical dextran, low molecular-weight dextran, heparin, and a saline control solution. These authors, however, administered a single dose of clinical dextran, low molecular-weight dextran, heparin, or saline solution, then based their conclusions regarding the efficacy of the preparations upon the incidence and extent of thrombosis which were observed 24 hours later. Earlier observations were made for the first 2 hours following their "standard trauma," but these earlier observations were not recorded in their report. Since the plasma clearance of low molecular-weight dextran is two to three times more rapid than that of clinical dextran (due to its lower molecular weight), similar blood levels over a 24-hour period should not persist following a single initial dose of the two agents. Furthermore, the effect of the intravenous administration of 1.5 mg per kilogram of heparin would rarely be expected to exert a therapeutic anticoagulant effect for longer than 4 to 6 hours. It is not surprising, therefore, that clinical dextran was concluded to be the most effective antithrombotic agent on comparing the magnitude of thrombosis after 24 hours. These investigators also reported "similar results" in paired vein segments subjected to a standard trauma, followed by direct infusion into one group of venous segments and systemic infusion into a similar group of venous segments. These observations are in direct conflict with those reported in this study. We have no ready explanation for this difference.
Bryant and associates9 using a standard trauma preparation for small arteries determined a 2-hour "thrombotic rate" of 52% for dextran with average molecular weight of 43,000, but only a 10% 2-hour "thrombotic rate" following infusion of clinical dextran (average molecular weight, 75,000). They correlated the efficacy of antithrombotic properties with the degree of change in coagulation factors, particularly alteration of the MA factor of the thromboelastogram, the prothrombin time, and the fibrin index time. They concluded that clinical dextran was the most effective agent tested in preventing thrombosis in small arteries following a "standard trauma, and that this effectiveness seemed to be related to the persistence of larger dextran molecules in the bloodstream following infusion.
Ernst and co-workers'1 described investigations of the efficacy of low molecularweight dextran in preventing venous thrombosis following a standardized trauma quite similar to our studies. They concluded that both their experimental and their clinical data indicated that low molecular-weight dextran was an effective agent in reducing the incidence of traumatic venous thrombosis and the propagation of the thrombus.
Sawyer and Moncrief,12 using sharply defined fractions lof varying molecular-weight dextrans and studying clot propagation, concluded that thrombus propagation was most effectively inhibited by dextran with a molecular weight of about 77,500. Their technique, however, was quite different from that used in our investigation in that the initial thrombus formed by the electrode system in a modified Williams and Carey preparation was removed at the end of the period of 1-hour current flow in the control group. The vessel was reopened 5 hours later, and thrombus propagation was used as an index of inhibition of thrombosis. Again, their studies demonstrated that a profound inhibition of clot propagation followed the infusion of dextran with a molecular weight of 77,500, but a significant degree of inhibition of thrombosis followed the infusion of dextrans with molecular weights ranging from 40,000 to 50,500. Clinical dextran with an average molecular weight of 75,000 subtends a much wider range of molecular weight (5 to 10% as high as 200,000, and 5 to 10% as low as 25,000) than the 77,500 molecular-weight preparation used by Sawyer and his associates.
Despite the variance in methods utilized by previous investigators, one may sum up these experiences by remarking that clinical dextran seems to be an effective inhibitor of venous thrombosis and interferes detectably with the coagulation mechanism of blood. Low molecular-weight dextran (average molecular weight, 40,000) also significantly inhibits venous thrombosis, but to a lesser extent in these previous studies than clinical dextran. It has the possible advantage, however, of producing no detectable effects upon the coagulation mechanism of blood.
In our own studies, we are unable to detect any difference between clinical dextran and low molecular-weight dextran in reducing venous thrombosis when the agent is administered by systemic infusion. When the various agents are given by direct perfusion over the injured venous segment, none of the agents seems to possess any superior antithrombotic property when compared with a control dextrose-saline solution. The method of administration (for example, direct perfusion into the injured vascular bed), therefore, may be considerably more important in the prevention of venous thrombosis or clot propagation than the specific agent perfused, provided that the vascular bed to be treated is accessible to direct infusion by feasible clinical methods.
Hydroxyethyl starch was included in this study because it is a plasma expander having similar properties and producing similar From an Early Report on Phlegmasia Dolens In the development of these facts, it will be my object to prove, or to attempt to prove, that the proximate cause of the disease called phlegmasia dolens, is a violent inflammation of one or more of the principal veins within and in the immediate neighbourhood of the pelvis, producing an increased thickness of their coats, the formation of false membranes on their internal surface, a gradual coagulation of their contents, and occasionally a destructive suppuration of their whole texture; in consequence of which, the diameters of the cavities of these important vessels become so greatly diminished, sometimes so totally obstructed as to be rendered mechanically incompetent to carry forward into their corresponding trunks the venous blood brought to them by their inferior contributory branches. 
